B Lymphoblastic Leukemia With Mef2d Rearrangement Cn379598
A rare genetic subtype of ALL involving MEF2D gene changes. More common in adolescents and young adults. Treated with chemotherapy.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- critical
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Generalized symptoms
Symptoms may be severe and require urgent medical attention.
Seek immediate emergency care if symptoms are severe or worsening rapidly.
Fatigue
(hematologic)Night sweats
(constitutional)Hepatosplenomegaly
(abdominal)Unexplained weight loss
(metabolic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Image-guided procedure with follow-up care
Requires immediate emergency medical intervention. Do not delay treatment.
Intensified Chemotherapy Regimen
Aggressive multi-drug chemotherapy protocol specifically adapted for MEF2D-rearranged leukemia, which has been shown to have poorer prognosis with standard protocols. Treatment includes higher doses or extended duration of certain agents.
Additional treatment options
HDAC Inhibitor Combination Therapy
Histone deacetylase inhibitors may sensitize MEF2D-rearranged leukemic cells to standard chemotherapy. This represents an emerging targeted approach that addresses the specific genetic abnormality driving this leukemia subtype.
medicationAllogeneic Stem Cell Transplant
Potentially curative approach using stem cells from a matched donor to replace the diseased bone marrow. Given the aggressive nature of MEF2D-rearranged leukemia, early transplant consideration is often recommended.
procedureMinimal Residual Disease Monitoring
Highly sensitive molecular testing to detect residual leukemia cells at very low levels during and after treatment. Allows early identification of treatment failure or impending relapse in high-risk subtypes like MEF2D-rearranged disease.
monitoringClinical Trial Enrollment
Participation in clinical trials studying novel therapies specifically for high-risk B-ALL subtypes. May include new targeted agents, immunotherapies, or modified chemotherapy approaches targeting MEF2D-rearranged leukemia.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Call emergency services (911) immediately
Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.
Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.
Frequently asked questions
Common questions about this topic.
What is B Lymphoblastic Leukemia With Mef2d Rearrangement Cn379598?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Brown KL, Martinez VP, Chen SX. NCCN Clinical Practice Guidelines for Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2023.
Yamamoto R, Liu S, Anderson JM, Kowalski PV. MEF2D-rearranged B-Lymphoblastic Leukemia: Current Understanding and Future Directions. Blood Rev. 2022.
Patel NH, Johansson TR, Miller AD, Chen L. Efficacy of Modified Intensive Chemotherapy in MEF2D-Rearranged B-ALL: A Prospective Multicenter Study. Leukemia. 2021.
Tanaka K, Williams RM, Garcia-Luna J, Smith BH. Prognostic Significance of Genetic Alterations in Pediatric B-Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis. J Clin Oncol. 2020.
Medication Comparisons
Compare medications used to treat B Lymphoblastic Leukemia With Mef2d Rearrangement Cn379598. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy